- Home
- CMCO vs NMRA Comparison
CMCO vs NMRA Comparison
Compare CMCO & NMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CMCO | NMRA |
|---|---|---|
| Founded | 1875 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Construction/Ag Equipment/Trucks | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 492.7M | 424.4M |
| IPO Year | 1996 | 2023 |
Fundamental Metrics
Financial Performance| Metric | CMCO | NMRA |
|---|---|---|
| Price | $20.52 | $2.17 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 9 |
| Target Price | ★ $35.00 | $8.00 |
| AVG Volume (30 Days) | 210.9K | ★ 2.2M |
| Earning Date | 02-09-2026 | 03-02-2026 |
| Dividend Yield | ★ 1.40% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.13 | N/A |
| Revenue | ★ $977,994,000.00 | N/A |
| Revenue This Year | $5.60 | N/A |
| Revenue Next Year | $4.23 | N/A |
| P/E Ratio | $152.64 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $11.78 | $0.61 |
| 52 Week High | $37.81 | $3.25 |
Technical Indicators
Market Signals| Indicator | CMCO | NMRA |
|---|---|---|
| Relative Strength Index (RSI) | 75.15 | 55.77 |
| Support Level | $17.13 | $2.06 |
| Resistance Level | $19.41 | $2.57 |
| Average True Range (ATR) | 0.74 | 0.22 |
| MACD | 0.20 | 0.06 |
| Stochastic Oscillator | 76.85 | 62.62 |
Price Performance
Historical ComparisonAbout CMCO Columbus McKinnon Corporation
Columbus McKinnon Corp is a designer, manufacturer, and marketer of intelligent motion solutions, including motion control products, technologies, automated systems, and services that efficiently and ergonomically move, lift, position, and secure materials. Its key products include hoists, crane components, precision conveyors, actuators, rigging tools, light rail workstations, and digital power and motion control systems. The company's targeted market verticals include general industries, process industries, industrial automation, and e-commerce/supply chain/warehousing among others. Geographically, the company generates a majority of its revenue from the United States and the rest from Germany, Canada, Asia Pacific, Latin America, Europe, the Middle East, and Africa.
About NMRA Neumora Therapeutics Inc.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.